José Carlos Menéndez, Mercedes Villacampa
612
42.
Gabhe, N.; Tasgoankar, R.; Dagade, B.; Rao, D.; Sawant, P.; Shirodkar, A. (2013). Dipeptidyl
peptidase IV (DPP-‐IV) inhibition: A novel approach for the treatment of type II diabetes
mellitus.
Int. J. Pharm. Sci
. 4, 629-‐637.
43.
Gupta, R.; Walung, S. S.; Tokala, R. K.; Parsa, K. V. L.; Singh, S. K.; Pal, M. (2009). Emerging
drug candidates of dipeptidyl peptidase IV (DPPP-‐IV) inhibitor class for the treatment of
type II diabetes.
Curr. Drug Targets
10, 71-‐87.
44.
Peters, J. W. (2007). 11 Years of cyanopyrrolidines as DPP-‐IV inhibitors.
Curr. Top. Med.
Chem
. 7, 579-‐595.
45.
Thoma, R.; Löffler, B.; Stihle, M.; Huber, W.; Ruf, A.; Hennig, M. (2003). Structural basis of
proline-‐specific exopeptidase activity as observed in human dipeptidyl peptidase-‐IV.
Structure
, 11, 947–959.
46.
Nabeno, M.; Akahoshi, F.; Kishida, H.; Miyaguchi, I.; Tanaka, Y.; Ishii, S.; Kadowaki, T.
(2013). A comparative study of the binding modes of recently launched dipeptidyl
peptidase IV inhibitors in the active site.
Biochem. Biophys. Res. Commun.
434, 191–196.
47.
Grigoriadis, D. E.; Hoare, S. R. J.; Lechner, S. M.; Slee, D. H.; Williams, J. A. (2009).
Drugability of extracellular targets: discovery of small molecule drugs targeting allosteric,
functional,
and subunit -‐selective sites on GPCRs and ion channels.
Ne ropsychopharmacology
34, 106–125.
48.
Willard, F. S.; Bueno, A. B.; Sloop, K. W. (2012). Small molecule drug discovery at the
Glucagon-‐Like Peptide-‐1 receptor.
Exptl.
Diabet.
Res
.,
article ID 709893,
doi:10.1155/2012/709893.
49.
He, M.; Guan, N.; Gao, W. W.; Liu, Q.; Wu, X.-‐Y.; Ma, D. W.; Zhong, D. F.; Ge, D. B.; Li, C.; Chen,
X. Y.; Yang, L.; Liao, J. Y.; Wang, M. W. (2012) A continued saga of Boc5, the first non-‐
in vivo activities.
Acta Pharmacol.
50.
(consultado el 05-‐08-‐2013).
51.
novel strategy for type 2 diabetes
ghts and perspectives
, capítulo 4.
Intech Open Science.
52.
Ansarullah, L. Y.; Holstein, M.; DeRuyter, B.; Rabinovitch, A.; Guo, Z. (2013) Stimulating b-‐
Cell regeneration by combining a GPR119 agonist with a DPP-‐IV inhibitor.
PLoS ONE
8(1),
53.
biology probes.
-‐
tado el 05-‐08-‐
